Trial Profile
Study of the Phosphoinositide-3-Kinase-Delta Inhibitor TGR-1202 in Patients With Relapsed or Refractory Follicular Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Umbralisib (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 11 Aug 2020 Status changed from recruiting to discontinued.
- 08 Jun 2017 New trial record